HLS Current Ratio from 2010 to 2026

HLS Stock  CAD 4.50  0.01  0.22%   
HLS Therapeutics Current Ratio yearly trend continues to be very stable with very little volatility. Current Ratio is likely to drop to 1.34. Current Ratio is a liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities. View All Fundamentals
 
Current Ratio  
First Reported
2010-12-31
Previous Quarter
1.41
Current Value
1.34
Quarterly Volatility
18.4506911
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check HLS Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HLS Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 13.2 M, Interest Expense of 12.2 M or Total Revenue of 55.7 M, as well as many indicators such as Price To Sales Ratio of 1.19, Dividend Yield of 0.0102 or PTB Ratio of 0.73. HLS financial statements analysis is a perfect complement when working with HLS Therapeutics Valuation or Volatility modules.
  
This module can also supplement various HLS Therapeutics Technical models . Check out the analysis of HLS Therapeutics Correlation against competitors.
Evaluating HLS Therapeutics's Current Ratio across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into HLS Therapeutics's fundamental strength.

Latest HLS Therapeutics' Current Ratio Growth Pattern

Below is the plot of the Current Ratio of HLS Therapeutics over the last few years. It is a liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities. HLS Therapeutics' Current Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in HLS Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 1.70 X10 Years Trend
Pretty Stable
   Current Ratio   
       Timeline  

HLS Current Ratio Regression Statistics

Arithmetic Mean8.61
Geometric Mean2.72
Coefficient Of Variation214.38
Mean Deviation11.51
Median1.58
Standard Deviation18.45
Sample Variance340.43
Range57.8128
R-Value(0.22)
Mean Square Error345.10
R-Squared0.05
Significance0.39
Slope(0.81)
Total Sum of Squares5,447

HLS Current Ratio History

2025 1.41
2024 1.57
2023 1.65
2022 1.42
2021 1.58
2020 1.29
2019 1.34

About HLS Therapeutics Financial Statements

HLS Therapeutics investors utilize fundamental indicators, such as Current Ratio, to predict how HLS Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Ratio 1.41  1.34 

Other Information on Investing in HLS Stock

HLS Therapeutics financial ratios help investors to determine whether HLS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.